Thermo Fisher Scientific plans to acquire point-of-care molecular diagnostics provider Mesa Biotech for $450 million in cash.
Thermo Fisher will pay up to an additional $100 million in cash upon the completion of certain milestones following the close of the deal.
The transaction is expected to be completed in the first quarter of 2021. Once finalized, the Mesa Biotech business will become part of Thermo Fisher's life sciences solutions segment.
